Pathogenesis of immune-mediated neuropathies

被引:69
|
作者
Dalakas, Marinos C. [1 ,2 ]
机构
[1] Univ Athens, Sch Med, GR-11527 Athens, Greece
[2] Thomas Jefferson Univ, Philadelphia, PA 19107 USA
关键词
Autoimmunity; Neuropathy; Ranvier; Immunotherapy; GUILLAIN-BARRE-SYNDROME; INFLAMMATORY DEMYELINATING POLYNEUROPATHY; MYELIN-ASSOCIATED GLYCOPROTEIN; PLACEBO-CONTROLLED TRIAL; COSTIMULATORY MOLECULE; CEREBROSPINAL-FLUID; INTRAVENOUS IMMUNOGLOBULIN; MONOCLONAL GAMMOPATHY; PERIPHERAL NEUROPATHY; THERAPEUTIC OPTIONS;
D O I
10.1016/j.bbadis.2014.06.013
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Autoimmune neuropathies occur when immunologic tolerance to myelin or axonal antigens is lost Even though the triggering factors and the underling immunopathology have not been fully elucidated in all neuropathy subsets, immunological studies on the patients' nerves, transfer experiments with the patients' serum or intraneural injections, and molecular fingerprinting on circulating autoantibodies or autoreactive T cells, indicate that cellular and humoral factors, either independently or in concert with each other, play a fundamental role in their cause. The review is focused on the main subtypes of autoimmune neuropathies, mainly the Guillain-Barre syndrome(s), the Chronic Inflammatory Demyelinating Polyneuropathy (CIDP), the Multifocal Motor Neuropathy (MMN), and the IgM anti-MAC-antibody mediated neuropathy. It addresses the factors associated with breaking tolerance, examines the T cell activation process including co-stimulatory molecules and key cytoldnes, and discusses the role of antibodies against peripheral nerve glycolipids or glycoproteins. Special attention is given to the newly identified proteins in the nodal, paranodal and juxtaparanodal regions as potential antigenic targets that could best explain conduction failure and rapid recovery. New biological agents against T cells, cytokines, B cells, transmigration and transduction molecules involved in their immunopathologic network, are discussed as future therapeutic options in difficult cases. This article is part of a Special Issue entitled: Neuromuscular Diseases: Pathology and Molecular Pathogenesis. (C) 2014 Elsevier B.V. All rights reserved.
引用
收藏
页码:658 / 666
页数:9
相关论文
共 50 条
  • [1] PATHOGENESIS OF IMMUNE-MEDIATED NEUROPATHIES
    ROSTAMI, AM
    PEDIATRIC RESEARCH, 1993, 33 (01) : S90 - S94
  • [2] Immune-mediated neuropathies - From pathogenesis to therapy
    Kieseier, B. C.
    Lehmann, H. C.
    Hartung, H. -P.
    AKTUELLE NEUROLOGIE, 2008, 35 (04) : 177 - +
  • [3] Immune-Mediated Neuropathies
    Mithila Fadia
    Sheetal Shroff
    Ericka Simpson
    Current Treatment Options in Neurology, 2019, 21
  • [4] Immune-Mediated Neuropathies
    Gwathmey, Kelly G.
    Smith, A. Gordon
    NEUROLOGIC CLINICS, 2020, 38 (03) : 711 - 735
  • [5] Immune-Mediated Neuropathies
    Schulte-Mattler, W. J.
    KLINISCHE NEUROPHYSIOLOGIE, 2014, 45 (04) : 186 - 192
  • [6] Immune-mediated neuropathies
    Bernd C. Kieseier
    Emily K. Mathey
    Claudia Sommer
    Hans-Peter Hartung
    Nature Reviews Disease Primers, 4
  • [7] Immune-mediated neuropathies
    Stoll, G.
    Reiners, K.
    NERVENARZT, 2016, 87 (08): : 887 - 898
  • [8] Immune-mediated neuropathies
    不详
    Nature Reviews Disease Primers, 4 (1) : 32
  • [9] Immune-mediated neuropathies
    Kieseier, Bernd C.
    Mathey, Emily K.
    Sommer, Claudia
    Hartung, Hans-Peter
    NATURE REVIEWS DISEASE PRIMERS, 2018, 4
  • [10] Immune-Mediated Neuropathies
    Fadia, Mithila
    Shroff, Sheetal
    Simpson, Ericka
    CURRENT TREATMENT OPTIONS IN NEUROLOGY, 2019, 21 (06)